What's Happening?
IntraBio Inc., a biopharmaceutical company based in Austin, Texas, has submitted a variation application to the European Medicines Agency (EMA) to expand the approved Marketing Authorization Application for AQNEURSA® (levacetylleucine) to include the treatment
of Ataxia-Telangiectasia (A-T). This marks the first regulatory application submitted to the EMA for a therapy targeting A-T, a rare and progressive neurodegenerative disorder. The application is pending EMA validation before formal scientific review begins. In the U.S., the Food and Drug Administration (FDA) has accepted IntraBio's supplemental New Drug Application for AQNEURSA for A-T and granted it Priority Review, with a target action date set for September 19, 2026. AQNEURSA is already approved in the European Economic Area for treating neurological manifestations of Niemann-Pick disease type C and in the U.S. for similar indications.
Why It's Important?
The submission of this application is significant as it could lead to the first approved therapy for Ataxia-Telangiectasia in the European Economic Area. A-T is a debilitating condition that affects coordination, speech, and increases the risk of cancer, with no current approved treatments. Approval of AQNEURSA could provide a much-needed therapeutic option for patients suffering from this disorder, potentially improving their quality of life. The Priority Review status granted by the FDA underscores the urgent need for effective treatments for rare diseases like A-T, highlighting the potential impact on public health and the biopharmaceutical industry.
What's Next?
If the EMA validates the application, a formal scientific review will commence, which could lead to the approval of AQNEURSA for A-T in Europe. In the U.S., the FDA's decision is expected by September 19, 2026. Approval in both regions could pave the way for further research and development in treatments for rare neurodegenerative diseases. Stakeholders, including patients, healthcare providers, and the biopharmaceutical industry, will be closely monitoring these developments, as successful approval could set a precedent for future therapies targeting similar conditions.
